Two months after the approval of the first biosimilar to infliximab, another Biologics License Application is now under FDA review.
Samsung Bioepis has announced that the FDA has accepted their Biologics License Application (BLA) for SB2, which the company has developed as a biosimliar to Johnson & Johnson's blockbuster drug infliximab (Remicade). The drug is an antiinflammatory agent, actively used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondilitis, psoriatic arthritis, and psoriasis.
Infliximab-dyyb is manufactured by Celltrion, Inc, based in the Republic of Korea, for Hospira.
According to a press release,
Today's announcement follows the approval of the first biosimilar to infliximab approved 2 months back in the US: infliximab-dyyb. Marketed by Pfizer, Samsung Bioepis’ BLA for SB2 was based on phase 1 and phase 3 clinical studies that tested the biosimilarity of SB2 to infliximab. In a 54-week phase 3 clinical study, SB2 showed comparable safety and equivalent efficacy to infliximab, as evidenced in ACR20 response rate of 65.3% in the SB2 arm versus 69.2% in the infliximab arm, fully supporting the 30-week study results of 64.1% and 66.0%, respectively. The SB2 study randomized 584 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries.
Samsung Bioepis is developing 13 other biosimilar drug candidates that span a broad range of therapeutic areas.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More